Serum Thyroid Function, Mortality and Disability in Advanced Old Age: The Newcastle 85+ Study

Simon H. S. Pearce, Salman Razvi, Mohammad E. Yadegarfar, Carmen Martin-Ruiz, Andrew Kingston, Joanna Collerton, Theo J. Visser, Tom B. Kirkwood, and Carol Jagger

Institute of Genetic Medicine (S.H.S.P., S.R.), Newcastle University, Newcastle upon Tyne NE1 3BZ, United Kingdom; Institute of Health and Society (M.E.Y., C.M.-R., A.K., J.C., T.B.K., C.J.), Newcastle University, Newcastle upon Tyne NE2 4AX, United Kingdom; and Department of Internal Medicine (T.J.V.), Erasmus Medical Center, Rotterdam, The Netherlands

Context: Perturbations in thyroid function are common in older individuals but their significance in the very old is not fully understood.

Objective: This study sought to determine whether thyroid hormone status and variation of thyroid hormones within the reference range correlated with mortality and disability in a cohort of 85-year-olds.

Design: A cohort of 85-year-old individuals were assessed in their own homes (community or institutional care) for health status and thyroid function, and followed for mortality and disability for up to 9 years.

Setting and Participants: Six hundred and forty-three 85-year-olds registered with participating general practices in Newcastle and North Tyneside, United Kingdom.

Main Outcomes: All-cause mortality, cardiovascular mortality, and disability according to thyroid disease status and baseline thyroid hormone parameters (serum TSH, FT4, FT3, and rT3). Models were adjusted for age, sex, education, body mass index, smoking, and disease count.

Results: After adjustment for age and sex, all-cause mortality was associated with baseline serum rT3 and FT3 (both \( P < .001 \)), but not FT4 or TSH. After additional adjustment for potential confounders, only rT3 remained significantly associated with mortality \( (P = .001) \). Baseline serum TSH and rT3 predicted future disability trajectories in men and women, respectively.

Conclusions: Our study is reassuring that individuals age 85 y with both subclinical hypothyroidism and subclinical hyperthyroidism do not have a significantly worse survival over 9 years than their euthyroid peers. However, thyroid function tests did predict disability, with higher serum TSH levels predicting better outcomes. These data strengthen the argument for routine use of age-specific thyroid function reference ranges. \( (J \text{ Clin Endocrinol Metab} 101:4385–4394, 2016) \)

Although overt thyroid dysfunction has long been associated with cardiovascular disease, the effects of subtle variations in thyroid function are less clear \((1–3)\).

Abbreviations: AF, atrial fibrillation; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; MI, myocardial infarction; MMSE, mini mental state examination; rT3, reverse T3.
the healthy reference interval for younger people (subclinical hyperthyroidism), and approximately 10% have an elevated serum TSH level (subclinical hypothyroidism) (4–7). The high prevalence of these mild or subclinical abnormalities of serum TSH with advancing age has led to a significant body of research concerning the possibility that these changes may presage ill health (2, 8–10). Similarly, the possibility that variations of serum TSH and circulating thyroid hormones even within the healthy reference range may predict current or future disease has also been examined (3, 11).

Twenty years ago, a low serum TSH level was first associated with an increased risk of atrial fibrillation (AF) (12), and this association has been reproduced many times since (13–16). Similarly, longitudinal studies have shown that a low serum TSH concentration is associated with a higher rate of cardiovascular events, osteoporotic fracture, dementia, and death (14, 17–20). However, there is significant heterogeneity within the literature, with some large and well-conducted studies failing to reproduce these associations (13, 21), as well as unresolved questions about causality. Similarly, several studies have found an association of elevated serum TSH with adverse cardiac outcomes, including myocardial infarction (MI), heart failure, and mortality (8, 10, 21–24). Nevertheless, these findings have not been reproduced by all studies (13, 17, 25, 26), suggesting that there may be heterogeneity between the populations studied, or confounding by comorbidities, medications, methodology or other unknown factors. Some authors have suggested that an elevated serum TSH in older age might have no adverse effect on health (7, 27, 28) although one study of individuals age 85 years showed that a high serum TSH at baseline was associated with a favorable outcome compared with that of euthyroid contemporaries (29). However, data from subjects in advanced old age is scarce and this finding has not been confirmed (2). Thus, mild biochemical abnormalities of thyroid function are common with increasing age but their significance remains unclear, particularly in the very old. In this study we examined the relationship between thyroid function and subsequent outcome in a cohort of 85-year-old individuals.

Participants and Methods

Participants and study design

Study participants were members of the Newcastle 85+ Study, a longitudinal study of health trajectories and outcomes in a single-year birth cohort (1921) recruited at age 85 years from general (family) practices in Newcastle and North Tyneside, which is described in detail elsewhere (30, 31). The recruited cohort was sociodemographically representative of the general United Kingdom population and included institutionalized older adults (31). At study baseline (2006/07), comprehensive measures of health were collected across multiple clinical, biological, and psychosocial domains. A health assessment—comprising questionnaires, anthropometric measurements, physical and cognitive function tests, and a fasting blood sample—was carried out in the participant’s usual residence by a research nurse. General practice medical records were also reviewed to extract data on diagnosed diseases and prescribed medication. In participants who were temporarily hospitalized at the time of recruitment, assessments were undertaken after discharge. All participants provided written informed consent except for those who lacked capacity to consent (for example, in dementia). For the latter group, an opinion was obtained from a close relative or carer, as required by UK law (32). The study was approved by the Newcastle and North Tyneside 1 Research Ethics Committee (Ref: 06/Q0905/2).

Health assessment, disease counts, and disability

The prevalence of common diseases was determined by evaluation of general practitioner records and/or health assessments. Diseases were scored as either present or absent for 17 selected chronic diseases and a disease count calculated as detailed previously (33). Briefly, these were: hypertension, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, atrial flutter or fibrillation, arthritis (osteoarthritis or rheumatoid arthritis), osteoporosis, chronic obstructive pulmonary disease or asthma, other respiratory disease, diabetes mellitus (type 1 or 2), cancer (diagnosed within the previous five years), eye disease, dementia, Parkinson’s disease, anemia, and renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m²) [methodology as reported in Collerton et al (31) but omitting thyroid disease from the disease count]. A disability score was created from 17 activities of daily living at baseline, 18 months, 36 months, and 60 months, and, using group-based trajectory modeling that accounted for mortality, four disability trajectories were identified for men and women separately (33). Information on date and cause of death (to ICD-10) were provided from linkage with the national registration system.

Blood samples and biochemical analysis

After an overnight fast, 40 mL blood was drawn from the antecubital vein between 0700 and 1030 hours. Blood sampling took place between June 2006 and August 2007. Measurement of TSH, FT₄, and FT₃ was performed using a Centaur platform (Seimens). Intra-assay coefficients of variation were serum TSH, 3.8% (at 5.3 mU/L); FT₄, 7.9% (at 13.5 pmol/L) and FT₃, 3.1% (at 10.5 pmol/L).
Serum reverse T3 (rT3) was assayed in duplicate by RIA, using antisera 3684 at a final dilution of 1:600 000 and sample volumes of 25 μL, as described (34). Thyroid peroxidase antibodies were assayed by Advia chemiluminescent assay on the Centaur platform with an intra-assay coefficient of variation of 17.7% at a concentration of 87.2 U/L. The following reference ranges were used: TSH, 0.4–4.0 mU/L; FT4, 11.0–23.0 pmol/L; FT3, 3.5–6.5 pmol/L; TPO antibodies, 0–60 U/L. Overt hypothyroidism was defined as TSH at least 10.00 mU/L or TSH, 4.01–9.99 mU/L and FT4 < 10.9 pmol/L; subclinical hypothyroidism was TSH, 4.01–9.99 mU/L and FT4 at least 11.0 pmol/L; euthyroid was TSH, 0.40–4.00 mU/L and FT4, 11.0–23.0 pmol/L; subclinical hyperthyroidism TSH < 0.399 mU/L, FT4 < 23.1, FT3 < 6.6; overt hyperthyroidism TSH < 0.099 and either FT4 > 23.0 pmol/L or FT3 at least 6.6 pmol/L/L. None of the participants classified as euthyroid from biochemical analysis had thyroid disease recorded in the general practice records.

Both health assessment and general practice records data were available for 845 participants at study baseline, of whom 760 had complete data on serum TSH, FT3, FT4, and rT3. An additional 116 were excluded as they were on thyroid medication or medication interfering with thyroid function (levothyroxine, antithyroid drugs, amiodarone, lithium, corticosteroids). One additional participant was excluded because she was diagnosed with hypopituitarism as part of the study assessments, leaving 643 participants whose mortality outcome was documented until January 1, 2015.

**Statistical analysis**

Differences in the baseline characteristics between the groups defined by biochemical status were assessed by χ² tests for the binary variables and Kruskal-Wallis for ordinal and continuous variables (none of which were normally distributed). The time interval for survival was calculated as that between time of blood draw and time of death or January 1, 2015. Kaplan-Meier plots were used to assess the relative risk of mortality by biochemical status separately by sex. Cox proportional hazards models were employed to explore the relative risk of mortality associated with each of the four serum thyroid measures separately (TSH, FT4, FT3, rT3) as continuous variables and for estimating hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted first, for age and sex (Model 1), and then for potential confounders: education (0–9 y, 10–11 y, 12 + y), body mass index (BMI), smoking (none, ex, current) and disease count (Model 2). Separate models were fitted to the entire and the euthyroid cohorts for all-cause mortality and cardiovascular mortality (ICD-10 codes I00-I99). The proportional hazards assumption was tested by examining the Schoenfeld residuals. Potential nonlinear relationships between each of the thyroid measures and all-cause and cardiovascular mortality were examined by fitting restricted cubic splines (35). The effect of the thyroid parameters on disability was examined by fitting ordinal logistic regression models adjusted for the potential confounders listed earlier. Analyses were undertaken in SAS version 9.4 (SAS Institute).

**Sensitivity analyses**

To compare our results more directly with the Leiden birth cohort of the same age (29), we repeated the Cox proportional hazards regression modeling adjusting for the same baseline covariates (age, sex, albumin, C-reactive protein [CRP], disease count, mini mental state examination [MMSE] score, disability score, subjective health).

During the first 5 years of the follow-up period, 21 participants were newly treated with levothyroxine and a further participant with antithyroid drugs. We repeated survival analyses excluding these 22 but the results remained the same (data not shown).

**Results**

**Mortality by thyroid status**

In this population of 643 85-year-olds, 83.1% (n = 534) were euthyroid at baseline, 12.5% (n = 79) had subclinical hypothyroidism, 2.9% (n = 19) had subclinical hyperthyroidism, and less than 1% were overtly hypothyroid (0.9%, n = 6) or hyperthyroid (0.8%, n = 5) (Table 1). Table 1 also shows the baseline characteristics for all participants (n = 643) and separately for those classified as euthyroid (n = 534). At baseline, biochemical thyroid status (including euthyroid, subclinical, and overt hypothyroidism) was associated with years in education (χ² = 10.86; df = 4; P = .028), medical history of ischemic heart disease (χ² = 9.27; df = 2; P < .001), serum albumin (F = 4.33; df = 2; P = .014), CRP (F = 5.06; df = 2; P = .007) and disability score (χ² = 7.29; df = 2; P = .03) (Supplemental Table 1).

Owing to the small number of overt hyper- and hypothyroid subjects, we combined the subclinical and overt biochemical categories for plotting the Kaplan-Meier curve for all-cause and cardiovascular mortality (Figure 1). No significant difference was found between the categories for all-cause mortality (male: P = .32; female: P = .54) or cardiovascular mortality (male: P = .94; female: P = .18). Nor was association found between thyroid status and either all-cause mortality or cardiovascular mortality after adjustment for age and sex, or after further adjustment for potential confounding factors (Supplemental Table 2).
Individual serum thyroid parameters

Analysis of each of the serum thyroid hormones individually showed that all-cause mortality was negatively associated with FT3 concentrations (HR = 0.81; 95% CI, 0.73–0.91; \( P < .001 \)) and positively associated with levels of rT3 (HR = 1.23; 95% CI, 1.12–1.34; \( P < .001 \)) although only rT3 remained significantly associated after adjustment for the potential confounding baseline factors of education, BMI, smoking status, and disease count (Table 2). Similar trends were found for cardiovascular mortality although, due to smaller number of deaths, the association of rT3 with cardiovascular mortality was no longer significant after adjustment for baseline factors (Table 2). When analyses were repeated for the subset of euthyroid participants (\( n = 534 \)), the same associations were found although all-cause mortality associations for both FT3 and rT3 remained significant after adjustment for baseline factors (Table 2).

Test of the proportional hazards assumptions showed that none of the variables violated the assumptions. Analysis of the individual thyroid hormones by restricted cubic splines to check for nonlinear associations with all-cause and cardiovascular mortality in the entire cohort showed that only FT3 had a nonlinear association with mortality, after adjustment for potential confounders, suggesting that both low and high FT3 (> 6.75 pmol/L) values were associated with increased all-cause mortality (Figure 2 and Supplemental Figure 1).

To examine whether our results were dependent upon the choice of confounders, we repeated analyses using the same confounding factors as Gussekloo et al (29), (age, sex, albumin, CRP, disease count, MMSE score, disability score, subjective health) and restricting survival to 4 years. Results were unchanged with only rT3 showing a significant relationship with mortality.

Disability

We examined the relationship between each of the thyroid function measures (TSH, FT3, FT4, rT3) and disability trajectory during the first 60 months of the study, for men and women separately (Table 3). The distributions of the thyroid hormones for each disability trajectory are shown in Supplemental Table 3. For women there was a significant trend toward increasing disability with decreasing

### Table 1. Baseline Characteristics of Study Sample

| Characteristic | Total (n = 643) | Euthyroid (n = 534) |
|----------------|----------------|-------------------|
| Age, y, mean (sd) | 85.5 (0.4) | 85.5 (0.4) |
| Male, % (n) | 42.0 (270) | 43.6 (233) |
| BMI, mean (sd) | 24.4 (4.4) | 24.5 (4.5) |
| Current smoker, % (n) | 5.6 (36) | 5.3 (28) |
| Basic education, % (n) | 63.6 (404) | 64.2 (339) |
| Living in care home, % (n) | 8.7 (56) | 8.6 (46) |
| Medical history, % (n) | | |
| Diabetes | 14.1 (91) | 14.2 (76) |
| Hypertension | 58.2 (374) | 59.0 (315) |
| IHD | 34.4 (221) | 37.3 (196) |
| Stroke | 13.8 (89) | 13.7 (73) |
| Cancer | 6.4 (41) | 6.2 (33) |
| Disease count, median (IQR) | 4 (3–6) | 4 (3–6) |
| Disability score, median (IQR) | 3 (1–7) | 3 (1–7) |
| MMSE score, median (IQR) | 28 (25–29) | 28 (25–29) |
| Fair or poor self-rated health, % (n) | 19.9 (120) | 20.9 (110) |
| Survival time, mo, median (IQR) | 65.6 (32.6–92.6) | 64.6 (32.4–91.1) |
| Deaths, % (n) | 68.4 (440) | 70.2 (375) |
| Cardiovascular deaths, % (n) | 39.2 (252) | 40.6 (217) |
| TSH*, mU/L | 1.87 (0.27–6.53) | 1.73 (0.58–3.80) |
| FT3, pmol/L | 4.54 (3.60–5.5) | 4.52 (3.60–5.40) |
| FT4, pmol/L | 15.20 (11.0–21.0) | 15.24 (11.0–20.0) |
| rT3, nmol/L | 0.40 (0.25–0.67) | 0.40 (0.26–0.67) |
| TPOAbs positive, % (n) | 15.9 (102) | 12.6 (67) |
| Albumin*, g/L | 40.03 (33.00–46.00) | 40.03 (33.00–46.00) |
| CRP, mg/L | 2.65 (0.30–52.20) | 2.67 (0.30–52.20) |
| Overt hypothyroid | 0.9 (6) | — |
| Subclinical hypothyroid | 12.3 (79) | — |
| Euthyroid | 83.1 (534) | 534 (100) |
| Subclinical hyperthyroid | 2.9 (19) | — |
| Overt hyperthyroid | 0.8 (5) | — |

Abbreviations: IHD, ischemic heart disease; IQR, interquartile range; TPOAbs, thyroid peroxidase antibodies.

*a Geometric mean, 2.5–97.5th percentiles
levels of TSH, FT₃, and increasing levels of rT₃, although after adjustment for potential confounders only rT₃ remained significantly associated with increased disability (Table 3). Trends for men were in a similar direction to women although after adjustment, only decreasing levels of TSH were predictive of increased disability. FT₄ was not associated with disability trajectory for either men or women.

Discussion

Mortality

The significance of mild disturbances of thyroid function in older individuals is poorly understood, particularly in the very old. The most frequent abnormality found is a raised serum TSH with circulating thyroid hormone concentrations that are within reference range, correlating with the state of subclinical hypothyroidism, and some studies suggest an adverse effect of this state (8, 10, 22, 24) whereas others show a neutral or even protective effect on outcome (2, 17, 25, 29, 36, 37). Notably, the Leiden 85+/H11001 study, a cohort study of 85-year-olds with a similar design to our study, found that subclinical hypothyroidism was associated with reduced all-cause mortality and cardiovascular mortality (29). This finding, along with the results of familial studies of the oldest old (7, 38), suggests that an elevated serum TSH may be positively associated with longevity and favorable outcomes in the very old. This led us and others to suggest that there may be age-related differences in the vascular risk associated with a raised serum TSH, with higher risks found in younger individuals that attenuated with advancing age (27, 39, 40). In the current study we have examined a substantial cohort of 85-year-olds and followed their outcome for up to 9 years. We find that baseline serum TSH had no substantial association with all-cause or vascular mortality in our cohort, which confirms the findings of many previous studies (2, 13, 17, 25, 29, 36), albeit in a cohort of older participants. These findings, therefore, provide further reassurance that subclinical hypothyroidism is a benign state in advanced older age (2, 29). Furthermore, we also show that variation of serum TSH within the reference interval is not associated with impaired survival. Indeed, perhaps parallel to the findings of the Leiden 85+/study (29), when only euthyroid participants were considered there is a hint of a protective effect of higher serum TSH on all-cause mortality, although this did not persist after adjustment for comorbidities. In addition, lower serum TSH was associated with disability in men, with a non-significant though similar trend in women. Whether there
could be a survival benefit associated with subclinical hypothyroidism at this age remains an open question, and our study does not exclude this possibility. However, sensitivity analysis in our cohort, using exactly the same adjustment factors as the Leiden 85+/H11001 study failed to reproduce this finding in participants of the same age, albeit in a later birth cohort.

In contrast with subclinical hypothyroidism, many previous studies have shown that low serum TSH is associated with poor outcomes, either increased all-cause or vascular mortality, or AF (12–14, 17, 29, 36, 37). This has led to suggestions that patients with low TSH should be aggressively treated for hyperthyroidism to avoid these complications despite a complete lack of compelling (level 1) evidence to support the effectiveness of this strategy (1, 41, 42). Although this current study does not support an increase in mortality associated with low TSH, there are relatively low number of participants with subclinical or overt hyperthyroidism in this study (24 in total), so this result is less robust than that for individuals with higher serum TSH concentrations or subclinical hypothyroidism. Nevertheless, the finding of no adverse effect associated with lower serum TSH concentration within the reference range is consistent with several other studies, and broadly reassuring.

Serum T₄ is metabolized either to the active thyroid hormone T₃ or to the inactive rT₃ in a reciprocal manner depending upon the relative actions of the tissue deiodinase enzymes (deiodinase types 1 to 3). Reduced circulating concentration of free T₃ is a sensitive marker of ill health (43). Indeed, fasting, cold exposure, and even minor infective or inflammatory disease are sufficient to reduce serum FT₃ and elevate rT₃ in otherwise-healthy individuals (44, 45). In our analysis, higher serum rT₃ was associated with all-cause mortality in the fully adjusted model: that is independent of prevalent disease burden. In contrast, lower FT₃ was also associated with both all-cause and cardiovascular mortality but following full correction for disease burden, these associations were lost. These findings broadly confirm those of previous studied cohorts of older people (2, 29), and are in line with the known pathophysiological mechanisms whereby low FT₃ and higher rT₃ are nonspecifically associated with increasing ill health and disease burden (44, 45). Interestingly, our analysis is one of only a few to look at serum rT₃ in individuals of this age, and our data suggest that high rT₃ is a stronger predictor of all-cause mortality than low FT₃, independent of disease burden. This finding is consistent with a longitudinal study of 403 Dutch males age 73–94 years in which a group with higher rT₃ but normal FT₃ had better performance status than those with lower FT₃ (43). One explanation may be that rT₃ is more sensitive to the

### Table 2. Relationship Between Thyroid Hormones and All-cause and Cardiovascular Mortality in the Full Cohort and in Euthyroid Participants; HRs (per Unit Increase) and 95% CIs

| Parameter | Model 1a | | Model 2b | |
|-----------|---------|-------------------|---------|-------------------|---------|
|            | HRc     | 95% CI           | P-Value | HRc     | 95% CI           | P-Value |
| Full cohort (n = 643) | | | | | |
| All-cause mortality | | | | | |
| TSH        | 0.92    | 0.78–1.09        | <.001   | 0.87    | 0.71–1.07        | .19     |
| FT₃        | 0.81    | 0.73–0.91        | <.001   | 0.91    | 0.81–1.01        | .08     |
| FT₄        | 1.09    | 0.99–1.21        | .01     | 1.07    | 0.96–1.19        | .22     |
| rT₃        | 1.23    | 1.12–1.34        | <.001   | 1.18    | 1.07–1.31        | .001    |
| Cardiovascular mortality | | | | | |
| TSH        | 1.03    | 0.88–1.19        | .001    | 0.96    | 0.74–1.25        | .76     |
| FT₃        | 0.85    | 0.74–0.97        | .01     | 0.97    | 0.84–1.12        | .70     |
| FT₄        | 1.03    | 0.90–1.17        | .001    | 0.99    | 0.86–1.15        | .93     |
| rT₃        | 1.22    | 1.08–1.38        | .001    | 1.13    | 0.99–1.29        | .07     |
| Euthyroid at baseline (n = 534) | | | | | |
| All-cause mortality | | | | | |
| TSH        | 0.64    | 0.43–0.95        | .027    | 0.72    | 0.47–1.09        | .12     |
| FT₃        | 0.75    | 0.66–0.84        | <.001   | 0.84    | 0.74–0.96        | .008    |
| FT₄        | 1.05    | 0.94–1.18        | .001    | 1.03    | 0.90–1.17        | .69     |
| rT₃        | 1.22    | 1.11–1.35        | <.001   | 1.17    | 1.05–1.31        | .006    |
| Cardiovascular mortality | | | | | |
| TSH        | 0.74    | 0.44–1.24        | .26     | 0.88    | 0.51–1.25        | .65     |
| FT₃        | 0.78    | 0.66–0.91        | .002    | 0.90    | 0.77–1.06        | .22     |
| FT₄        | 1.00    | 0.86–1.17        | .006    | 0.96    | 0.81–1.13        | .61     |
| rT₃        | 1.21    | 1.06–1.38        | .006    | 1.10    | 0.95–1.28        | .20     |

a Adjusted for age and sex
b Adjusted for age, sex, education, BMI, smoking, disease count
c HR per SD increase of: 3.223 mIU/L TSH, 0.496 pmol/L FT₃, 2.470 pmol/L FT₄, 0.109 nmol/L rT₃.
presence of preclinical morbidities (eg, early tissue inflammation or covert cancer); the alternative being that our disease count incorporating 17 common conditions is incomplete and that serum rT3 is sensitive to uncounted conditions not included in the adjustment. Our deeper examination of the relationship between thyroid hormones and mortality by fitting cubic splines showed that most of the hormones were linearly related to mortality. The exception was FT3 where both low and high values were predictive of mortality in the very old.

Disabilities
Scant data exist about the relationship between thyroid function, functional status, and future disability in this age group (43, 46, 47). Our analysis showed that baseline serum TSH, FT3, and rT3 each predicted future disability with the strongest effects seen in women. However, given that these associations are attenuated following adjustment by baseline disease count and BMI, these factors may be on the causal pathway between thyroid function and disability. The association of disability with lower TSH in
men is particularly interesting given that, in cohort studies, subclinical hyperthyroidism or lower serum TSH have been associated with many involutional disease states including dementia, osteoporosis, AF, muscle weakness, low bone density, and fracture (12–14, 18, 20, 48, 49). It has widely been assumed that these associations are caused by subclinical hyperthyroidism with detrimental effects of excess thyroid hormone, for instance its proarrhythmic effect on the heart leading to AF, despite the fact that serum thyroid hormones are within reference range (1, 13–15, 29, 41, 42). Our findings that lower serum TSH predicts future disability, even when adjusted for baseline disease count, suggests that in advanced old age, lower TSH (and in the unadjusted analysis, lower FT₃/higher rT₃) correlates with an increasing burden of nonthyroidal disease. This is consistent with the Health ABC study, showing that in a cohort with a mean age of 75 years, the group with higher serum TSH (4.5–6.99 mU/L) had faster gait speed and better cardiorespiratory fitness than those with lower TSH (46).

**Limitations**

Our prospective observational study has some limitations. A relatively low number of individuals were studied and so with lower numbers of vascular events, there was less power to detect a significant difference in cardiovascular deaths, compared with all-cause mortality. However, this is still the largest study of this kind in this age group, as far as we are aware. In addition, we assessed 17 common comorbid conditions for which we adjusted in our multivariate analyses. It is possible that there may be other less common yet influential conditions that have not been taken into account. Furthermore, similar to most other longitudinal observational cohort studies, there may be a bias toward healthier people participating. In particular, it seems probable that individuals with sensory impairments may have been under-represented in the cohort. Nevertheless, in contrast with most studies of this age group, we did include participants with advanced frailty living in supervised care and nursing homes as well as those with dementia, so our results should be representative for age-matched populations. Thus, these self-evident potential limitations, as well as other unknown confounders, may also have influenced the results of our study.

**Summary**

In a cohort of 85-year-olds, baseline serum rT₃ was associated with all-cause mortality during a 9-year period of followup, and may be a more sensitive marker for nonthyroidal illness than FT₃. No significant mortality associations were found with serum TSH, FT₃, or FT₄. However, in men lower serum TSH, and in women higher rT₃ predicted disability. Although it is well established that low FT₃ is associated with nonthyroidal illness, our findings are consistent with reduced serum TSH also being a marker for disability in older age. These data suggest that there is little detriment associated with subclinical hypothyroidism in this age group.

**Acknowledgments**

We thank Mr. Steve Turner of the Royal Victoria Infirmary Biochemistry laboratories for invaluable assistance with thyroid hormone assays.

Address all correspondence and requests for reprints to: Simon Pearce, Institute for Genetic Medicine, Newcastle University, In...
ternational Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, United Kingdom. E-mail: simon.pearce@ncl.ac.uk.

The Newcastle 85+ Study was funded by the Medical Research Council (Grant No. G0500997), the Biotechnology and Biological Sciences Research Council, the Dunhill Medical Trust, the NIHR Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Hospitals Healthcare Charity and Newcastle University.

Disclosure Summary: S.H.S.P. has received speaker fees from Merck, and for consultation with Viropharma & Shire. S.R., R.L.B., J.C., T.J.V., T.B.K., and C.J. have nothing to disclose.

References

1. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142–1154.
2. Waring AC, Arnold AM, Newman AB, Bužková P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: The cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97:3944–3950.
3. Taylor PN, Razvi S, Pearce SH, Dayan CM. A review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab. 2013;98:3562–3571.
4. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39–51.
5. Somwaru LL, Rarly CM, Arnold AM, Cappola AR. The natural history of subclinical hypothyroidism in the elderly: The cardiovascular health study. J Clin Endocrinol Metab. 2012;97:1962–1969.
6. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489–499.
7. Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab. 2009;94:1231–1234.
8. Hak AE, Pols HA, Visser TJ, Drexlage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med. 2000;132:270–278.
9. Nanchen D, Gusselkloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab. 2012;97:852–861.
10. Razvi S, Weaver JU, Vanderpump MP, Pearce SHS. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: Reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95:1734–1740.
11. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab. 2015;100:1088–1096.
12. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–1252.
13. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033–1041.
14. Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): Morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96:1344–1351.
15. Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: A large population cohort study. BMJ. 2012;345:e7895.
16. Heeringa J, Hogendoorn EH, et al. High-normal thyroid function and risk of atrial fibrillation: The Rotterdam study. Arch Intern Med. 2008;168:2219–2224.
17. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklin JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001;358:861–865.
18. Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk: A meta-analysis. JAMA 2015;313:2055–2065.
19. Collet TH, Gusselkloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799–809.
20. Gän EH, Pearce SH. Clinical review: The thyroid in mind: Cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab. 2012;97:3438–3449.
21. Walsh JP, Brenner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467–2472.
22. Imaiizu M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hyperthyroidism. J Clin Endocrinol Metab. 2004;89:3365–3370.
23. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: An individual participant data analysis from 6 prospective cohorts. Circulation 2012;126:1040–1049.
24. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010;304:1365–1374.
25. Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hyperthyroidism and cardiovascular risk in the elderly: The cardiovascular health study. J Clin Endocrinol Metab 2013;98:533–540.
26. Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN, Garry PJ. Impact of subclinical hyperthyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid. 2003;13:595–600.
27. Razvi S, Shakoor A, Weaver JU, Vanderpump M, Weaver JU Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: A metaanalysis. J Clin Endocrinol Metab. 2008;93:2998–3007.
28. Ochs N, Auer R, Bauer DC, Nanchen D, Gusselkloo J, Cornuz J, Rodondi N. Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832–845.
29. Gusselkloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591–2599.
30. Collett J, Barrass K, Bond J, et al. The Newcastle 85+ study: Biological, clinical and psychosocial factors with healthy ageing: Study protocol. BMC Geriatr. 2007;7:14.
31. Collett J, Davies K, Jagger C, et al. Health and disease in 85 year olds: Baseline findings from the Newcastle 85+ cohort study. BMJ. 2009;339:b4904.
32. Parliament (UK): Mental Capacity Act. 2005, Stationery Office.
33. Kingston A, Davies K, Collett J, et al. The enduring effect of education-socioeconomic differences in disability trajectories from age 85 years in the Newcastle 85+ Study. Arch Gerontol Geriatr. 2015;60:405–411.
34. Visser TJ, Docter R, Hennemann G. Radioimmunoassay of reverse tri-iodothyronine. J. Endocrinol 1977;73:395–396.
35. Duruleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:531–561.
36. Ceresini G, Ceda GP, Lauretani F, et al. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: The Aging in the Chianti Area Study. J Am Geriatr Soc. 2013;61:868–874.
37. Ceresini G, Marina M, Lauretani F, et al. Relationship between circulating thyroid-stimulating hormone, free thyroxine, and free...
triiodothyronine concentrations and 9-year mortality in euthyroid elderly adults. *J Am Geriatr Soc*. 2016;64:553–560.

38. Jansen SW, Akintola AA, Roelfsema F, et al. Human longevity is characterised by high thyroid stimulating hormone secretion without altered energy metabolism. *Sci Rep*. 2015;5:11525.

39. Mariotti S, Cambuli VM. Cardiovascular risk in elderly hypothyroid patients. *Thyroid*. 2007;17:1067–1073.

40. Pasqualetti G, Tognini S, Polini A, Caraccio N, Monzani F. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? *J Clin Endocrinol Metab*. 2013;98:2256–2266.

41. Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. *Eur Thyroid J*. 2015;4:149–163.

42. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Endocr Pract* 2011;17:456–520.

43. van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. *J Clin Endocrinol Metab*. 2005;90:6403–6409.

44. Spencer CA, Lum SM, Wilber JF, Kaptein EM, Nicoloff JT. Dynamics of serum thyrotropin and thyroid hormone changes in fasting. *J Clin Endocrinol Metab*. 1983;56:883–888.

45. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. *J Endocrinol*. 2015;225:R67–R81.

46. Simonsick EM, Newman AB, Ferrucci L, et al. Subclinical hypothyroidism and functional mobility in older adults. *Arch Intern Med* 2009;169:2011–2017.

47. Simonsick EM, Chia CW, Mammen JS, Egan JM, Ferrucci L. Free thyroxine and functional mobility, fitness and fatigue in euthyroid older men and women in the Baltimore longitudinal study of aging. *J Gerontol A Biol Sci Med Sci* 2016;71(7):961–967.

48. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. *Clin Endocrinol (Oxf)*. 2000;53:733–737.

49. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS. The impact of overt and subclinical hyperthyroidism on skeletal muscle. *Thyroid*. 2006;16:375–380.